|Articles|November 4, 2014

The Strategy Behind LabCorp's Acquisition of Covance

Here is a summary of what analysts are saying about LabCorp's purchase of Covance.

A couple of analyst reports on LabCorp’s purchase of Covance and how it affects investors crossed our email since the announcement early yesterday. What was provided by the analysts—more than the financial investing aspects—was an interesting look at the direction of clinical trials, labs, and the future of drug development. Here is a summary of what these analysts are saying about the purchase.

Growth to larger biopharma market. The Maxim Group says the transaction diversifies LabCorp’s revenue beyond the $62B clinical testing industry into the $141B biopharma R&D market. Deutsche Bank says the entry into relatively higher-growth end-market, with CRO outsourcing growing 7% to 8% and Covance is recognized for its strong capabilities across key service offerings, as the number one central lab, number one pre-clinical, and among the top five CROs offering Phase I-IV services.

Creates a unique clinical trial offering. The Maxim Group also suggests that the combined entity will benefit from the emerging personalized medicine and companion diagnostic revolution. It positions the company to introduce a unique clinical trial offering on the front end to biopharma customers that no other CRO can offer and a personalized medicine offering on the backend to patients and MCOs that no other clinical lab can provide.

Blended labs and logistics. As the fifth largest shipping company in the world, LabCorp’s logistical expertise can be introduced within Covance’s business. Maxim Group maintains that both companies operate central labs—LabCorp has four central labs and 44 regional labs; Covance has five central labs. Given that much of LabCorp’s business is processed at night, its labs are largely underutilized during the day. The greater scale and shift away from time sensitive volume, should allow the company with the opportunity to consolidate facilities without having to close any central labs. In addition, analysts William Blair say the combined LabCorp and Covance clinical trials central lab business could have about 50% market share post-deal.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 6th, 2026

What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to the region.

November 6th, 2026

ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment

In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.

Ten key risk indicators can flag recurring good clinical practice problems in noncompliance, safety, data quality, and oversight, but only when normalization, trial timing, and combined signals are taken into account. Credit: Stock.Adobe.com/Andrey Popov.

November 6th, 2026

The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent

Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

November 5th, 2026

Why Outdated Perceptions of APAC Clinical Trial Sites Persist Among Smaller Biotechs

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how regulatory reform and inspection data contradict the view that APAC sites are slower or lower quality, and why sponsors need to update their assumptions.

November 5th, 2026

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health

In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.

November 5th, 2026

ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal

In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.

November 4th, 2026

Comparing OpenAI and Mistral on Clinical Trial Matching

Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.

November 4th, 2026

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time

In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.